Skip to main content
. Author manuscript; available in PMC: 2010 Mar 2.
Published in final edited form as: Gastroenterology. 2005 Aug;129(2):682–695. doi: 10.1016/j.gastro.2005.05.050

Table 1.

Physiological Analysis and ET-1 Levels in CBDL- and TAA-Treated Animals

CBDL
 TAA
Variable Control 1 Wk 2 Wk 3 Wk 2 Wk 8 Wk
PVP (mm Hg) 7.4 ± 0.3 11.1 ± 0.7a 14.0 ± 0.6a 15.2 ± 0.9a 9.6 ± 0.8a 12.6 ± 1.8a
Spleen weight (g) 0.7 ± 0.1 0.8 ± 0.1 1.3 ± 0.1a 1.6 ± 0.1a 0.6 ± 0.1 0.9 ± 0.1a
AaPo2 (mm Hg) 7.5 ± 1.5 7.8 ± 2.7 17.9 ± 1.7a 19.4 ± 2.9a 10.4 ± 3.7 12.9 ± 2.7
Intrapulmonary shunt fraction (%) 5.8 ± 0.1 6.1 ± 1.3 12.0 ± 2.4a 14.0 ± 3.0a 6.1 ± 0.1 6.6 ± 0.1
Liver ET-1 (ng/g tissue) 2.4 ± 0.3 5.2 ± 0.8a 5.7 ± 0.7a 8.6 ± 1.6a 2.5 ± 0.5 3.0 ± 0.4
Plasma ET-1 (pg/mL) 6.9 ± 0.2 20.0 ± 1.0a 17.4 ± 0.7a 22.6 ± 2.5a 8.9 ± 0.4 8.6 ± 1.0

NOTE. Values are mean ± SE (n = 5–8 animals per group).

ET, endothelin; CBDL, common bile duct ligation; TAA, thioacetamide; PVP, portal venous pressure; AaPo2, alveolar–arterial oxygen gradient.

a

P < .05 compared with normal control.